These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26936390)

  • 21. Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells.
    Kim HI; Seo SK; Chon SJ; Kim GH; Lee I; Yun BH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
    Hurwitz JL; Stasik I; Kerr EM; Holohan C; Redmond KM; McLaughlin KM; Busacca S; Barbone D; Broaddus VC; Gray SG; O'Byrne KJ; Johnston PG; Fennell DA; Longley DB
    Eur J Cancer; 2012 May; 48(7):1096-107. PubMed ID: 22154545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
    Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
    Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
    Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
    J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).
    Basu HS; Mahlum A; Mehraein-Ghomi F; Kegel SJ; Guo S; Peters NR; Wilding G
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):705-15. PubMed ID: 20512578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
    Qiu X; Rong X; Yang J; Lu Y
    BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
    Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):673-8. PubMed ID: 15637150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion.
    You BR; Park WH
    Oncol Rep; 2016 Jan; 35(1):546-51. PubMed ID: 26530353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
    Jiang X; Tsang YH; Yu Q
    Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effects of Molecular Hydrogen and Suberoylanilide Hydroxamic Acid on Paraquat-Induced Production of Reactive Oxygen Species and TNF-α in Macrophages.
    Li J; Wu X; Chen Y; Zeng R; Zhao Y; Chang P; Wang D; Zhao Q; Deng Y; Li Y; Alam HB; Chong W
    Inflammation; 2016 Dec; 39(6):1990-1996. PubMed ID: 27624060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors in programmed cell death and cancer therapy.
    Marks PA; Jiang X
    Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.